Cardinal Health Inc
CAH: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$451.00 | Wlbhp | Ttddkhlvt |
Narrow-Moat Cardinal Health Enters 2023 With Strong Sales From Pharmaceuticals; FVE Remains at $67
Narrow-moat Cardinal Health reported fiscal second-quarter earnings that were slightly ahead of our assumptions. The top line for the quarter increased 13.2% year over year, driven by pharmaceutical (up 15.2%) and offset by medical (down 7.1%). We maintain our fair value estimate of $67 per share.